AMARIN CORP PLCUK

Amarin Corp PLC reported a net loss of $(10.5) million for Q1 2026, an improvement from $(15.7) million in Q1 2025, with total revenue increasing to $45.1 million from $42.0 million. The company recognized $3.3 million in restructuring expenses during the quarter as part of its Global Restructuring Plan, which has incurred cumulative charges of $39.6 million. Despite revenue growth, gross margin declined, and cash and cash equivalents decreased.

Amarin reported Q1 2026 total net revenue increased 7% to $45.1 million, driven by higher international sales and licensing revenue. The company significantly narrowed its net loss by 33% to $10.5 million and generated positive cash flow for the second consecutive quarter, reiterating its full-year positive cash flow expectation. The refined global business model, including the European partnership with Recordati, and updated industry guidelines supporting icosapent ethyl (IPE) contributed to the positive outlook.

Amarin Corporation plc reported Q1 2026 financial results, with total net revenue increasing 7% to $45.1M and net loss narrowing 33% to $(10.5)M. The company generated positive cash flow for the second consecutive quarter and reiterated its expectation for full-year positive cash flow. International sales, particularly from its European partnership with Recordati, showed early measurable progress, while the U.S. franchise maintained market share with VASCEPA-branded prescriptions rising 17% YoY.